Baxter International (BAX) closed at $23.00 on October 30, 2026, down 2.1% from the previous close, on volume of 10,840,355 shares (30-day average 6,724,177).
Data as of October 30, 2026.
30-Oct-2026
Notable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focus
Seeking Alpha News (Sun, 1-Nov 9:05 AM ET)
Healthcare sector rallies in October amid rotation away from technology stocks
Seeking Alpha News (Sat, 31-Oct 11:05 AM ET)
Baxter International Earnings Call Highlights Growth And Risks
TipRanks (Fri, 30-Oct 8:22 PM ET)
TipRanks (Fri, 30-Oct 9:50 AM ET)
TipRanks (Fri, 30-Oct 6:54 AM ET)
Baxter International (BAX) Gets a Sell from Barclays
TipRanks (Fri, 30-Oct 5:47 AM ET)
Baxter falls despite double beat, boosting guidance
Seeking Alpha News (Thu, 29-Oct 12:04 PM ET)
Baxter’s Q3 2026 results pair 5% organic sales growth with a raised full-year outlook
Market Chameleon (Thu, 29-Oct 4:08 AM ET)
Baxter Raises 2026 Guidance and Declares Quarterly Dividend
TipRanks (Thu, 29-Oct 7:45 AM ET)
Baxter Non-GAAP EPS of $0.58 beats by $0.06, revenue of $2.98B beats by $70M
Seeking Alpha News (Thu, 29-Oct 7:17 AM ET)
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Baxter International trades on the NYSE stock market under the symbol BAX.
As of October 30, 2026, BAX stock price declined to $23.00 with 10,840,355 million shares trading.
BAX has a beta of 0.91, meaning it tends to be less sensitive to market movements. BAX has a correlation of 0.06 to the broad based SPY ETF.
BAX has a market cap of $11.89 billion. This is considered a Large Cap stock.
Last quarter Baxter International reported $3 billion in Revenue and $.58 earnings per share. This beat revenue expectation by $69 million and exceeded earnings estimates by $.06.
In the last 3 years, BAX traded as high as $44.01 and as low as $15.73.
The top ETF exchange traded funds that BAX belongs to (by Net Assets): VTI, VOO, VB, RSP, VBR.
BAX has outperformed the market in the last year with a return of +20.3%, while the SPY ETF gained +12.3%. However, in the most recent history, BAX shares have underperformed the stock market with its stock returning -14.0% in the last 3 month period and -9.0% for the last 2 week period, while SPY has returned +2.1% and -1.0%, respectively.
BAX support price is $22.95 and resistance is $24.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BAX shares will trade within this expected range on the day.
